← Leaderboards
Edward Ayson Motea
Indiana University Indianapolis
$1,677,769
Attributed
$2,238,242
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $965.7K · FY2019–22$1M$750K$500K$250K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$2,238,242 · 3
By mechanism
R01$1,830,699 · 2
R21$407,543 · 1
Top collaborators
- Xiumei Huang3 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Xiumei Huang$4,132,015
- Karson Putt$4,609,248
- Reuben Kapur$21,257,649
- Elliot J Androphy$24,340,128
- David W. Clapp$30,065,006
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseLeadResponseCellsDna DamageAffectOverexpressionResistanceTumorMalignant NeoplasmsRepairedDna RepairCancer CellIn VitroMutantHydrogen PeroxideKnock-DownNeoplastic CellClinical TrialsMalignant Neoplasm Of LungBystander EffectLungGrantCancer Therapy
Grant awards (7)
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$356,044
R01 · FY2022 · CA
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$381,823
R01 · FY2021 · CA
Development of a novel biochemical tool with tumor-selective theranostic anti-cancer potential$185,247
R21 · FY2021 · CA · contact PI
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer$383,079
R01 · FY2020 · CA
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity$360,281
R01 · FY2020 · CA · contact PI
Development of a novel biochemical tool with tumor-selective theranostic anti-cancer potential$222,296
R21 · FY2020 · CA · contact PI
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity$349,472
R01 · FY2019 · CA · contact PI